Irritable Bowel Syndrome (IBS) Treatment Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends
Discover trends, market shifts, and competitive outlooks for the irritable bowel syndrome (ibs) treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Anticipated CAGR of the Irritable Bowel Syndrome (IBS) Treatment Market, and What Factors Will Drive It?
The market size for treatment of irritable bowel syndrome (IBS) has witnessed rapid expansion in recent years. The market is projected to escalate from $2.79 billion in 2024 to approximately $3.07 billion by 2025, with a compound annual growth rate (CAGR) of 10.2%. The considerable growth observed in the historic period is a result of factors including the rising incidence of IBS, escalating patient awareness, the impact of stress and lifestyle, existence of patient advocacy and support groups, and favorable healthcare reimbursement policies.
The market size for the treatment of irritable bowel syndrome (IBS) is forecast to experience significant growth in the coming years. The market is projected to expand to $4.93 billion by 2029, with a compound annual growth rate (CAGR) of 12.5%. This predicted growth can be linked to various factors such as the introduction of patient-focused healthcare models, microbial therapies, the incorporation of blockchain in the healthcare sector, patient-reported outcomes (pros), accelerated regulatory schemes, and data interoperability in health. Key trends for the forecasted period involve the adoption of digital health technologies, advancements in diagnostic methods, a boost in research and development investments, increased collaborations, partnerships, and the rise of non-pharmacological therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp
Which Primay Drivers Are Accelerating Growth in the Irritable Bowel Syndrome (IBS) Treatment Market?
The escalating instances of irritable bowel syndrome (IBS) are anticipated to bolster the progress of the IBS treatment market in the future. IBS is a persistent disorder of the gastrointestinal system that affects the colon. The escalation in IBS instances can be attributed to poor lifestyle choices, unhealthy dietary habits, exposure to pollutants, and heightened stress levels. Interventions for IBS aids in lessening the severity and regularity of IBS symptoms, enhancing the quality of life, and equipping individuals to deal with their circumstances more effectively. For example, the International Foundation for Gastrointestinal Disorders (IFFGD), a non-profit research and education agency based in the US, claimed that about 5–10% of the world population is diagnosed with IBS in 2023, and between 25 and 45 million US citizens are suffering from IBS. Consequently, the escalating instances of irritable bowel syndrome (IBS) are spurring the growth of the IBS treatment market.
Which Primary Segments of the Irritable Bowel Syndrome (IBS) Treatment Market Are Driving Growth and Industry Transformations?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented –
1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=11978&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Irritable Bowel Syndrome (IBS) Treatment Market?# Market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Irritable Bowel Syndrome (IBS) Treatment Industry Dynamics?
Product advancements have been identified as an escalating trend gathering momentum in the irritable bowel syndrome (IBS) market. Major players in the IBS market are focusing their energy on designing fresh, novel, and high-quality products to solidify their market presence. For instance, in April 2022, Ardelyx, an American biotech firm, introduced IBSRELA, a groundbreaking treatment for IBS-C in adults. This is the premier and singular NHE3 inhibitor on the market for treating adult irritable bowel syndrome with constipation (IBS-C). Being the first Ardelyx drug to obtain FDA approval, IBSRELA is presented as the first new mechanistic therapy for IBS-C (irritable bowel syndrome-constipation) in nearly a decade, offering an imperative new therapeutic alternative for constipation, bloating, and abdominal discomfort, which are all symptoms of this debilitating malady.
View the full report here:
What Parameters Are Used to Define the Irritable Bowel Syndrome (IBS) Treatment Market?
Irritable bowel syndrome (IBS) treatment refers to the various approaches and interventions aimed at treating gastrointestinal tract disorders, which are frequent disorders that affect the stomach and intestines. It is used to alleviate constipation, diarrhea, and abdominal symptoms, minimize the frequency and severity of flare-ups, and enhance overall well-being.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
